Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population

Authors: Chaymaa Marouf, Stella Göhler, Miguel Inacio Da Silva Filho, Omar Hajji, Kari Hemminki, Sellama Nadifi, Asta Försti

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Breast cancer (BC) is the most prevalent cancer in women and a major public health problem in Morocco. Several Moroccan studies have focused on studying this disease, but more are needed, especially at the genetic and molecular levels. Therefore, we investigated the potential association of several functional germline variants in the genes commonly mutated in sporadic breast cancer.

Methods

In this case–control study, we examined 36 single nucleotide polymorphisms (SNPs) in 13 genes (APOBEC3A, APOBEC3B, ARID1B, ATR, MAP3K1, MLL2, MLL3, NCOR1, RUNX1, SF3B1, SMAD4, TBX3, TTN), which were located in the core promoter, 5’-and 3’UTR or which were nonsynonymous SNPs to assess their potential association with inherited predisposition to breast cancer development. Additionally, we identified a ~29.5-kb deletion polymorphism between APOBEC3A and APOBEC3B and explored possible associations with BC. A total of 226 Moroccan breast cancer cases and 200 matched healthy controls were included in this study.

Results

The analysis showed that12 SNPs in 8 driver genes, 4 SNPs in APOBEC3B gene and 1 SNP in APOBEC3A gene were associated with BC risk and/or clinical outcome at P ≤ 0.05 level. RUNX1_rs8130963 (odds ratio (OR) = 2.25; 95 % CI 1.42-3.56; P = 0.0005; dominant model), TBX3_rs8853 (OR = 2.04; 95 % CI 1.38-3.01; P = 0.0003; dominant model), TBX3_rs1061651 (OR = 2.14; 95 % CI1.43-3.18; P = 0.0002; dominant model), TTN_rs12465459 (OR = 2.02; 95 % confidence interval 1.33-3.07; P = 0.0009; dominant model), were the most significantly associated SNPs with BC risk. A strong association with clinical outcome were detected for the genes SMAD4 _rs3819122 with tumor size (OR = 0.45; 95 % CI 0.25-0.82; P = 0.009) and TTN_rs2244492 with estrogen receptor (OR = 0.45; 95 % CI 0.25-0.82; P = 0.009).

Conclusion

Our results suggest that genetic variations in driver and APOBEC3 genes were associated with the risk of BC and may have impact on clinical outcome. However, the reported association between the deletion polymorphism and BC risk was not confirmed in the Moroccan population. These preliminary findings require replication in larger studies.
Literature
1.
Bray F et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45.CrossRefPubMed
2.
Ferlay J, S.I., Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Internet; Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://​globocan.​iarc.​fr, accessed on 05/02/2014., 2012.
3.
4.
Cai Q, Long J, Lu W, et al. Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Hum Mol Genet. 2011;20:4991–9.PubMedCentralCrossRefPubMed
5.
6.
Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer. 2010;10:353–61.CrossRefPubMed
7.
Gold B, Kirchhoff T, Stefanov S, et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A. 2008;105:4340–5.PubMedCentralCrossRefPubMed
8.
Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39:870–4.PubMedCentralCrossRefPubMed
9.
Long J, Cai QY, Sung H, et al. Genome-wide association study in East Asians identifies novel susceptibility loci for breast cancer. PLoS Genet. 2012;8, e1002532.PubMedCentralCrossRefPubMed
10.
Long J, Cai Q, Shu XO, et al. Identification of a functional genetic variant at 16q12.1 for breast cancer risk: results from the Asia Breast Cancer Consortium. PLoS Genet. 2010;6, e1001002.PubMedCentralCrossRefPubMed
11.
Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2007;39:865–9.CrossRefPubMed
12.
Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008;40:703–6.CrossRefPubMed
13.
Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet. 2009;41:579–84.PubMedCentralCrossRefPubMed
14.
Turnbull C, Ahmed S, Morrison J, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet. 2010;42:504–7.PubMedCentralCrossRefPubMed
15.
Zheng W, Long J, Gao YT, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet. 2009;41:324–8.PubMedCentralCrossRefPubMed
16.
Michcailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45:353–61.CrossRef
17.
Antoniou AC et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet. 2010;42:885–92.PubMedCentralCrossRefPubMed
18.
Fletcher O et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst. 2011;103:425–35.CrossRefPubMed
19.
20.
21.
Siddiq A et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012;21:5373–84.PubMedCentralCrossRefPubMed
22.
23.
Bojesen SE et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013;45:371–84.PubMedCentralCrossRefPubMed
24.
Milne RL et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2014.
25.
Cai Q et al. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat Genet. 2014;46:886–90.PubMedCentralCrossRefPubMed
26.
Stephens P et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet. 2005;37:590–2.CrossRefPubMed
27.
28.
29.
Sjoblom T et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268–74.CrossRefPubMed
30.
Kumar A et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A. 2011;108:17087–92.PubMedCentralCrossRefPubMed
31.
32.
33.
Wood LD et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–13.CrossRefPubMed
34.
35.
Willer CJ, Speliotes EK, Loos RJ, et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet. 2009;41:25–34.PubMedCentralCrossRefPubMed
36.
Stankiewicz P, Lupski JR. Structural variation in the human genome and its role in disease. Annu Rev Med. 2010;61:437–55.CrossRefPubMed
37.
Long J, Delahanty RJ, Li G, Gao YT, Lu W, Cai Q, et al. A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst. 2013;105:573–9.PubMedCentralCrossRefPubMed
38.
Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 2007;3(4):63.CrossRef
39.
Xuan D, Li G, Cai Q, Deming-Halverson S, Shrubsole MJ, Shu XO, et al. APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis. 2013;34:2240–3.
40.
41.
Ellis MJ et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353–60.PubMedCentralPubMed
42.
Shah SP et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–9.PubMed
43.
Wedekind JE, Dance GS, Sowden MP, Smith HC. Messenger RNA editing in mammals: new members of the apobec family seeking roles in the family business. Trends Genet. 2003;19:207–16.CrossRefPubMed
44.
45.
Suspene R et al. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc Natl Acad Sci U S A. 2011;108:4858–63.PubMedCentralCrossRefPubMed
46.
Komatsu A et al. Identification of novel deletion polymorphisms in breast cancer. Int J Oncol. 2008;33:261–70.PubMed
47.
48.
49.
Fang HY et al. Proteomic identification of differentially expressed proteins in curcumin-treated MCF-7 cells. Phytomedicine. 2011;18:697–703.CrossRefPubMed
50.
Chimge NO, Frenkel B. The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene. 2013;32:2121–30.CrossRefPubMed
51.
52.
Tamborero D et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013;3:2650.PubMedCentralPubMed
53.
Douglas NC, Papaioannou VE. The T-box transcription factors TBX2 and TBX3 in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2013;18:143–7.PubMedCentralCrossRefPubMed
54.
Fan W, Huang X, Chen C, Gray J, Huang T. TBX3 and its isoform TBX3 + 2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. Cancer Res. 2004;64:5132–9.CrossRefPubMed
55.
Lomnytska M, Dubrovska A, Hellman U, Volodko N, Souchelnytskyi S. Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients. Int J Cancer. 2006;118:412–21.CrossRefPubMed
56.
Washkowitz AJ et al. Diverse functional networks of Tbx3 in development and disease. Wiley Interdiscip Rev SystBiol Med. 2012;4:273–83.CrossRef
57.
Granzier HL, Labeit S. Titin and its associated proteins: the third myofilament system of the sarcomere. Adv Protein Chem. 2005;71:89–119.CrossRefPubMed
58.
59.
60.
Zastrow MS, Flaherty DB, Benian GM, Wilson KL. Nuclear Titin interacts with A- and B-type lamins in vitro and in vivo. J Cell Sci. 2006;119:239–49.CrossRefPubMed
61.
Woltmann A et al. Systematic pathway enrichment analysis of a genome-wide association study on breast cancer survival reveals an influence of genes involved in cell adhesion and calcium signaling on the patients’ clinical outcome. PLoS One. 2014;9:98229.CrossRef
62.
Davis FM, et al. Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene. 2013;33:2307-16.
63.
Tanaka A, Weinel S, Nagy N, O'Driscoll M, Lai-Cheong JE, Kulp-Shorten CL, et al. Germline mutation in ATR in autosomal-dominant oropharyngeal cancer syndrome. Am J Hum Genet. 2012;90:511–7.
64.
Smith L, Liu SJ, Goodrich L, Jacobson D, Degnin C, Bentley N, et al. Duplication of ATR inhibits MyoD, induces aneuploidy and eliminates radiation-induced G1 arrest. Nature Genet. 1998;19:39–46.
65.
66.
Peasland A et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer. 2011;105:372–81.PubMedCentralCrossRefPubMed
67.
68.
69.
Durocher F et al. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer. 2006;6:230.PubMedCentralCrossRefPubMed
70.
Metadata
Title
Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population
Authors
Chaymaa Marouf
Stella Göhler
Miguel Inacio Da Silva Filho
Omar Hajji
Kari Hemminki
Sellama Nadifi
Asta Försti
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2210-8

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Scenario drafting for early technology assessment of next generation sequencing in clinical oncology

Study protocol

Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial

Research article

Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma

Research article

The usefulness of 18F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD)

Research article

Casein kinase 1α has a non-redundant and dominant role within the CK1 family in melanoma progression

Study protocol

The effect of neoadjuvant chemotherapy and chemoradiotherapy on exercise capacity and outcome following upper gastrointestinal cancer surgery: an observational cohort study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits